Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.
Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
34 minutes ago
- Globe and Mail
Why Wall Street is Watching Broadcom $250 Ahead of Earnings
With mega-cap tech giant Broadcom (AVGO) set to report earnings after the close on June 5, momentum is building — and the smart money is already positioning itself. Let's break down why AVGO this could be one of the most important earnings plays of the season. Wall Street's Bold $301 Price Target Analyst Mike Harrison from Redburn Atlantic just initiated AVGO with a 'Buy' rating and a Street-high target of $301, citing Broadcom's dominance in the ASIC (application-specific integrated circuit) space. These chips power the artificial intelligence (AI) revolution — and AVGO is quietly becoming one of its most vital players. Congress Bought the Dip Two U.S. politicians, Reps. Kelly Morrison and Michael McCaul, disclosed AVGO purchases in April. Congressional buys don't always mean bullish moves — but when they line up with institutional flow and analyst upgrades, it's worth watching. Gamma Exposure Above $250 Barchart's Gamma Exposure Tool shows a high concentration of positive gamma above $250. This means market makers are hedging against big moves — often leading to price stability near these levels. But that stability doesn't last forever. As earnings approach, any break of key gamma levels could lead to powerful directional moves. Expected Move for Earnings Use Barchart's Expected Move Tool to map the projected high and low ranges for AVGO after earnings. This tool uses options pricing to calculate where the stock could land post-report. This is essential for planning straddle/strangle strategies, risk-reward ratios, or knowing when to scale in/out of positions. Trade Setups Are Already Triggering Barchart's trading strategies have flagged multiple bullish signals on AVGO throughout April and May, including moving average crossovers and trend confirmation setups. That's a strong confirmation that momentum has already shifting higher in anticipation of earnings. However, the recent surge higher has left AVGO stock short-term overbought, based on its 14-day Relative Strength Index (RSI) of 82.01, which means a post-earnings reversal on any negative news is a very real possibility. How to Prep for AVGO Earnings Like a Pro Review the Expected Move Range Check Gamma Exposure Levels Watch for updates in Analyst Ratings Look at historical Seasonal Returns Stream our latest AVGO Reel Breakdown Watch In Under 60 Seconds: Explore the Tools
Globe and Mail
34 minutes ago
- Globe and Mail
Cathie Wood Trims Tesla Stock (TSLA) Ahead of Robotaxi Launch—Is it a Red Flag for Investors?
Cathie Wood, one of Tesla's most prominent long-term bulls, made a surprising move by trimming her Tesla (TSLA) holdings weeks before the company's highly anticipated Robotaxi reveal. As excitement builds around Elon Musk's autonomous vision, ARK Invest's sudden Tesla sell-off has raised eyebrows across Wall Street. Confident Investing Starts Here: For context, Wood's ARK Innovation ETF (ARKK) sold nearly 50,000 Tesla shares last week. This includes 27,377 on Tuesday, 15,817 on Wednesday, and 6,511 on Friday, totaling around $17 million, according to recent trade disclosures. Meanwhile, Tesla is set to launch its Robotaxi service, featuring self-driving CyberCab vehicles, which will offer on-demand rides in Austin starting on June 12. What It Means for Investors While ARK's latest Tesla sell-off may look alarming, it's worth noting that Cathie Wood routinely trims oversized positions to rebalance her portfolio. This move likely signals profit-taking or strategic diversification, not a complete loss of faith. That said, the timing is notable. With Tesla's highly anticipated Robotaxi launch looming, some investors may wonder if ARK is hedging against short-term uncertainty. After all, autonomous driving technology is still unproven at scale, and if Tesla's rollout doesn't meet expectations, market sentiment could shift quickly. For retail investors, ARK's partial exit could be a quiet warning to avoid getting caught up in the hype. Tesla Retains Top Spot in ARKK Despite recent share sales, ARKK remains deeply invested in Tesla, demonstrating strong long-term conviction. Wood has been a steadfast Tesla bull, fueled by her confidence in the company's potential to dominate the robo-taxi market. Earlier in March, ARKK set an ambitious price target of $2,600 for Tesla shares by 2029. Wood's optimistic forecast is grounded in the belief that Tesla's robotaxis will drive nearly 90% of the company's value by the end of the decade. Overall, Tesla remains the largest holding in the ARKK fund, comprising nearly 13% of its portfolio. Are Tesla Shares a Good Buy? On Wall Street, analysts have maintained a neutral stance on Tesla stock. According to TipRanks, TSLA stock has received a Hold consensus rating, with 16 Buys, 10 Holds, and 11 Sells assigned in the last three months. The average Tesla stock price target is $282.7, suggesting a potential downside of 17.5% from the current level. See more TSLA analyst ratings Disclaimer & Disclosure Report an Issue
CTV News
44 minutes ago
- CTV News
Trump doubles metals tariffs, adding fuel to trade war. Live updates here.
U.S. President Donald Trump has increased tariffs on steel and aluminum imports from 25 per cent to 50 per cent. The presidential proclamation went into force at 12:01 a.m. EDT Wednesday. In that document, Trump said the new rate would better counter 'foreign countries that continue to offload low-priced, excess steel and aluminum,' undercutting the U.S. market. Ottawa called the additional levies 'unlawful and unjustified.' About a quarter of all steel used in the United States is imported and Canada is its largest supplier. Follow along for the latest updates: 'Unlawful and unjustified': PMO responds In a statement to CTV News Tuesday night, the Prime Minister's Office (PMO) called the additional tariffs on steel and aluminum 'unlawful and unjustified.' 'Canada's new government is engaged in intensive and live negotiations to have these and other tariffs removed as part of a new economic and security partnership with the United States,' the statement said. The PMO added that every dollar collected from Canada's retaliatory tariffs over $90 billion, before remissions, will go to 'supporting Canadian workers and businesses impacted by the harmful U.S. tariffs.' 'We are fighting to get the best deal for Canada, and we will take the time necessary, but no longer,' the PMO said. Lynn Chaya , journalist, and Stephanie Ha , Ottawa News Bureau journalist. Read the full story here . Mark Carney: Donald Trump trade war Prime Minister Mark Carney speaks to media following the First Minister's Meeting in Saskatoon, Sask., Monday, June 2, 2025. THE CANADIAN PRESS/Liam Richards (Liam Richards) Moving energy from Eastern Canada A plan to generate and transmit energy from Eastern Canada to other markets has been prioritized as a 'nation-building' project, following a meeting with the premiers and Prime Minister Mark Carney. The Eastern Energy Partnership would link hydro and wind power from Atlantic Canada and Quebec to destinations in Western Canada and U.S. states in New England. An initial cost of $8 billion has been tagged for transmission infrastructure. Nova Scotia Premier Tim Houston said a portion of the plan, dubbed 'Wind West,' would send energy from the province's offshore wind zones via a transmission cable. 'Nova Scotia's Wind West project can produce enough energy that is the equivalent of powering up to 27 per cent of the country's needs,' said Houston in a social media video post Monday evening. Nick Moore , journalist. Read the full story here . Mark Carney news Prime Minister Mark Carney, left, speaks to media following the First Minister's Meeting in Saskatoon, Sask., Monday, June 2, 2025. THE CANADIAN PRESS/Liam Richards (Liam Richards/The Canadian Press) Carney: Chinese tariffs a 'top priority' The federal government plans to work urgently to remove Chinese tariffs on Canadian agriculture and seafood products, Carney said Monday. 'The Canadian government is engaging with its Chinese counterparts at the ministerial level, and we'll continue those discussions,' Carney told reporters after meeting with premiers in Saskatoon. 'They're a top priority for us.' The commitment, which came in a statement after the meeting, says premiers want Canada's trading relationship with China to improve. The Canadian Press. Read the full story here . Canada seafood Canadian flags on fishing boats on Grand Manan island New Brunswick on Thursday, May 8, 2025. THE CANADIAN PRESS/Graham Hughes U.S. and Europe discuss tariffs in Paris Europe and the United States are meeting in Paris to negotiate a settlement of a tense tariff spat with global economic ramifications between two global economic powerhouses. The European Union's top trade negotiator, Maroš Šefčovič, met Wednesday with his American counterpart, U.S. Trade Representative Jamieson Greer, on the sidelines of a meeting of the Organization for Economic Cooperation and Development. 'We're advancing in the right direction at pace — and staying in close contact to maintain the momentum,' Šefčovič posted on social media platform X alongside a photo of him shaking hands with Greer. Brussels and Washington are unlikely to reach a substantive trade agreement in Paris. The issues dividing them are too difficult to resolve quickly. The Associated Press. Read the full story here . Belgium EU U.S. Trade European Commissioner for Trade and Economic Security Maros Sefcovic arrives for a meeting of EU trade ministers at the European Council building in Brussels, Thursday, May 15, 2025. (AP Photo/Omar Havana) (Omar Havana/AP) OECD: Trade war takes toll on U.S. economy Global economic growth is slowing more than expected from only a few months ago as the fallout from the Trump administration's trade war takes a bigger toll on the U.S. economy, the OECD said on Tuesday, revising down its outlook. The global economy is on course to slow from 3.3 per cent last year to 2.9 per cent in 2025 and 2026, the Organization for Economic Cooperation and Development said, trimming its estimates from March for growth of 3.1 per cent this year and three per cent next year. But the growth outlook would likely be even weaker if protectionism increases, further fuelling inflation, disrupting supply chains and rattling financial markets, the Paris-based organization said in its latest economic outlook. 'Additional increases in trade barriers or prolonged policy uncertainty would further lower growth prospects and likely push inflation higher in countries imposing tariffs,' OECD Secretary General Mathias Cormann said as he presented the report.
